专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

41. 发明授权

US08815931B2 Oral formulations for tetrapyrrole derivatives 有权
标题翻译：四吡咯衍生物的口服制剂
公开(公告)号：US08815931B2
公开(公告)日：2014-08-26
申请号：US12768244
申请日：2010-04-27
申请人： Susanna Gräfe , Nikolay Nifantiev , Albrecht Volker , Wolfgang Neuberger , Gerhard Wieland , Dietrich Scheglmann , Alfred Fahr , Arno Wiehe
发明人： Susanna Gräfe , Nikolay Nifantiev , Albrecht Volker , Wolfgang Neuberger , Gerhard Wieland , Dietrich Scheglmann , Alfred Fahr , Arno Wiehe
IPC分类号： A61K31/40 , A61K9/127 , A61K31/498 , A61K9/00 , A61K31/409
CPC分类号： A61K31/409 , A61K9/0065 , A61K9/127 , A61K9/1271 , A61K31/498
摘要： Oral formulations and method of formulating photosensitive agents for oral administration during photodynamic therapy (PDT) and Antimicrobial photodynamic therapy (APDT) treatment are presented. The oral formulated photosensitizers show increased solubility and permeability, thus improving the bioavailability of photosensitizers at the treatment site. An orally administered photosensitizer is suitably formulated for mucosal adhesion and absorption via gastrointestinal mucosal membranes. Oral formulation provided herein use lipids and known proteins as carriers for photosensitizers by oral route. Carriers for encapsulating preselected photosensitizers include conventional liposomes, pegylated liposomes, nanoemulsions, nanocrystrals, nanoparticles, fatty emulsions, lipidic formulations, hydrosols, SMEDDS, Alpha-Feto protein (AFP), and Bovine-Serum-Albumin (BSA), fatty emulsions, hot-melt-extrudates and nanoparticles. The oral formulation, in case of a hydrophobic photosensitizer in the present invention, is stabilized using suitable surfactants/solubilizers thus preventing aggregation of the drug in the stomach and until it is absorbed in the duodenum and the small intestine. Oral formulations can be administered in the form of liquid, capsule, tablet, powder, paste or gel. Formulated drugs can be administered orally as one single dose or in multiple doses before administering PDT. In one embodiment Temoporfin (m-THPC) is used as a photosensitizer in the oral formulations. Temoporfin like many hydrophobic photosensitizers are especially suitable to be administered orally because there is no known enzyme system in the mammalian body which can metabolize Temoporfin or similar photosensitizers. Temoporfin can reach the blood system unchanged and fully active after absorption of the formulation in the gastrointestinal tract.
摘要翻译：提出了在光动力治疗（PDT）和抗微生物光动力疗法（APDT）治疗中配制口服光敏剂的口服制剂和方法。口服配制的光敏剂显示增加的溶解度和渗透性，从而提高光敏剂在治疗部位的生物利用度。口服给药的光敏剂适于配制用于通过胃肠粘膜进行粘膜粘附和吸收。本文提供的口服制剂通过口服途径使用脂质和已知蛋白质作为光敏剂的载体。用于封装预选光敏剂的载体包括常规脂质体，聚乙二醇化脂质体，纳米乳剂，纳米胶体，纳米颗粒，脂肪乳剂，脂质制剂，水溶胶，SMEDDS，α-铁蛋白（AFP）和牛血清白蛋白（BSA），脂肪乳剂，热熔融挤出物和纳米颗粒。在本发明的疏水性光敏剂的情况下，使用合适的表面活性剂/增溶剂稳定口服制剂，从而防止药物在胃中的聚集，直到其被吸收到十二指肠和小肠中。口服制剂可以以液体，胶囊，片剂，粉末，糊剂或凝胶的形式施用。配制药物可以在给予PDT之前以一次剂量或多次剂量口服给药。在一个实施方案中，Temoporfin（m-THPC）用作口服制剂中的光敏剂。类似于许多疏水性光敏剂的Temoporfin特别适合于口服给药，因为哺乳动物体内没有已知的可以代谢Temoporfin或类似光敏剂的酶系统。 Temoporfin可以在胃肠道吸收制剂后达到血液系统不变和充分活性。

42. 发明授权

US08801764B2 Cosmetic laser treatment device and method for localized lipodystrophies and flaccidity 有权
标题翻译：化妆品激光治疗装置及局部脂肪营养不良及易感性的方法
公开(公告)号：US08801764B2
公开(公告)日：2014-08-12
申请号：US11415782
申请日：2006-05-02
申请人： Danilo Castro Suarez , Wolfgang Neuberger
发明人： Danilo Castro Suarez , Wolfgang Neuberger
IPC分类号： A61N5/06 , A61B18/20 , A61B18/24 , A61B18/00 , A61B18/22 , A61B17/00
CPC分类号： A61B18/22 , A61B18/20 , A61B18/24 , A61B2017/00792 , A61B2018/00464 , A61B2018/0047 , A61B2018/00577 , A61B2018/2272
摘要： A method and device for cosmetic surgery, especially fat reduction and collagen reformation, by means of a high power laser operating at about 980 nm is presented. The cosmetic surgery method substantially reduces or removes localized lipodystrophies, and essentially reduces flaccidity by localized laser heating of adipose tissue using an optical fiber inserted into a treatment area. The method and device are particularly well suited for treating Lipodystrophies with flaccidity High power laser energy is applied to “fat” cells to breakdown the cell walls releasing the cell fluid. The laser radiation is applied through an optical fiber which may be held within a catheter-like device having a single lumen. The optical fiber may have a diffuser mounted on the tip to further apply heating to tissues surrounding the whole tip. A saline solution may also be inserted into the treatment site to aid in the heating of the fat cells and their eventual destruction as well as their removal. The pool of cell fluid in the area of treatment is removed by a combination of techniques including allowing the body to remove it by absorption and drainage from the entry sites thus minimizing trauma to the area of treatment and hastening recovery. Additional techniques to remove the cell fluid include direct force application by means of elastic bandages and external suction applied to the entry sites. Quick and lasting cosmetic changes, even in areas having prior untreatable fat tissues, are achieved while minimizing trauma to the treatment areas.
摘要翻译：提出了一种用于整容手术的方法和装置，特别是通过在约980nm下操作的高功率激光来减脂和胶原蛋白重整。整容手术方法基本上减少或去除局部的脂肪营养不良，并且通过使用插入到治疗区域中的光纤对脂肪组织的局部激光加热来基本上减少松弛。该方法和装置特别适合用于治疗具有松弛性的脂肪营养不良。大功率激光能量被施加到“脂肪”细胞上以破坏释放细胞液的细胞壁。激光辐射通过可以保持在具有单个管腔的导管状装置内的光纤施加。光纤可以具有安装在尖端上的扩散器，以进一步对整个尖端周围的组织施加加热。也可以将盐水溶液插入治疗部位，以帮助加热脂肪细胞及其最终的破坏以及其去除。治疗区域中的细胞液池通过技术的组合来去除，包括允许身体通过进入部位的吸收和排出而将其去除，从而最小化对治疗区域和加速恢复的创伤。除去细胞液的附加技术包括通过弹性绷带施加的直接力施加和施加到入口部位的外部吸力。即使在具有先前不可治愈的脂肪组织的区域中也能实现快速和持久的化妆品变化，同时最小化治疗区域的创伤。

43. 发明授权

US08709004B2 Method and device for vascular treatment 有权
标题翻译：用于血管治疗的方法和装置
公开(公告)号：US08709004B2
公开(公告)日：2014-04-29
申请号：US12755948
申请日：2010-04-07
申请人： Julio H. G. Ferreira , Jorge O. Löpez D'Ambola , Wolfgang Neuberger , Antonio C. Reichelt , Jorge E. Soracco
发明人： Julio H. G. Ferreira , Jorge O. Löpez D'Ambola , Wolfgang Neuberger , Antonio C. Reichelt , Jorge E. Soracco
IPC分类号： A61B18/18
CPC分类号： A61B18/00 , A61B18/06 , A61B18/08 , A61B18/1492 , A61B18/24 , A61B2018/00023 , A61B2018/00029 , A61B2018/00404 , A61B2218/002
摘要： A method and device for improved minimally invasive vascular treatments. The method comprises introducing a catheter into a vein to be treated. The catheter is adapted to introduce an energy transmitting member and a fluid into the vein to be treated. The fluid introduced via the catheter can include, but is not limited to: saline solutions, cooled saline solutions, liquids for vapor generation, vasoconstricting agents, anesthetic agents and/or a formulation containing an ingredient which can be activated by the applied energy.
摘要翻译：用于改善微创血管治疗的方法和装置。该方法包括将导管引入待治疗的静脉中。导管适于将能量传递构件和流体引入待治疗的静脉中。通过导管引入的流体可以包括但不限于：盐水溶液，冷却的盐水溶液，用于蒸气产生的液体，血管收缩剂，麻醉剂和/或含有可被施加的能量活化的成分的制剂。

44. 发明授权

US08414880B2 PDT treatment method for cellulites and cosmetic use 失效
标题翻译：用于脂肪团和化妆品使用的PDT处理方法
公开(公告)号：US08414880B2
公开(公告)日：2013-04-09
申请号：US12899003
申请日：2010-10-06
申请人： Danilo Castro , Wolfgang Neuberger
发明人： Danilo Castro , Wolfgang Neuberger
IPC分类号： A01N63/00
CPC分类号： A61K31/555 , A61K8/494 , A61K31/409 , A61K2800/81 , A61Q19/06
摘要： Photosensitizer mixtures and method of treating cellulites by light illumination are presented. Photosensitizer is combined with cellular products, e.g. adipose cells, collagen, previously removed by liposuction. Concentrations used depend on treatment area, cellulite stage and whether cellulites are in depressed or elevated skin areas. The cosmetic treatment reduces/removes localized lipodystrophies, flaccidity, cellulite using localized laser, LED, etc emissions. Applied light energy destroys “fat” cells by a combination of chemical reactions primarily, and temperature, wherein cell walls break releasing cell fluid. Transmission devices guide radiation to the treatment site. One or more light sources like laser diodes or LEDs may be coupled into one or more optical fibers to increase the covered area and increase the amount of radiation in that area. Optical fibers can be introduced percutaneously or interstitially. Cell fluid in the treatment area is removed by a combination of techniques.
摘要翻译：提出了光敏剂混合物和通过光照照治疗脂肪团的方法。光敏剂与蜂窝产品结合，例如脂肪细胞，胶原蛋白，预先通过吸脂除去。使用的浓度取决于治疗区域，脂肪团阶段以及是否在脂肪团处于抑郁或升高的皮肤区域。化妆处理减少/消除了使用局部激光，LED等排放的局部脂肪营养不良，松弛，脂肪团。应用光能主要通过化学反应的组合和温度破坏脂肪细胞，其中细胞壁破坏释放细胞液体。传输装置将辐射引导到治疗部位。诸如激光二极管或LED的一个或多个光源可以耦合到一个或多个光纤中，以增加覆盖面积并增加该区域中的辐射量。光纤可经皮或间质引入。通过技术的组合来去除处理区域中的细胞液。

45. 发明授权

US08409176B2 Method and device for laser lithotripsy 失效
标题翻译：激光碎石术的方法和装置
公开(公告)号：US08409176B2
公开(公告)日：2013-04-02
申请号：US12628634
申请日：2009-12-01
申请人： Walter Cecchetti , Wolfgang Neuberger , Leonardo Cecchetti
发明人： Walter Cecchetti , Wolfgang Neuberger , Leonardo Cecchetti
IPC分类号： A61B17/22
CPC分类号： A61B18/26 , A61B18/24 , A61B2017/2215 , A61B2018/00029 , A61B2018/263
摘要： A system/method for destruction/ablation of stones, calculi or other hard substances using laser is disclosed. Lithotripsy is particularly benefitted. The system comprises a diode laser source, one or more optical fibers and a liquid delivery system creating a liquid environment around stones (calculi). At least one emitted wavelength is highly absorbed in surrounding/covering medium, causing evaporation and cavitation effects that lead to stone/calculi destruction. Different radiation configurations may be used. in one embodiment continuous radiation is used to create sparkler-less plasma bubbles to destroy hard substances. In another embodiment high peak power pulsed radiation is used. Wavelengths of 1470 nm, 1940 nm, or 1550 nm are preferred. Additionally device/method is used with another wavelength having absorption in water e.g. 980 nm. Safer/improved methods/system provide enhanced lithotripsy treatments with shorter treatment times to destroy a wider range of stones with less tissue damage risk.
摘要翻译：公开了使用激光破坏/消融石块，结石或其他硬物质的系统/方法。碎石术特别受益。该系统包括二极管激光源，一个或多个光纤以及在石头（结石）周围产生液体环境的液体输送系统。至少一个发射波长在周围/覆盖介质中被高度吸收，导致导致石头/结石破坏的蒸发和气蚀效应。可以使用不同的辐射配置。在一个实施例中，连续辐射用于产生无闪蒸的等离子体气泡以破坏硬物质。在另一个实施例中，使用高峰值功率脉冲辐射。优选1470nm，1940nm或1550nm的波长。另外装置/方法用于在水中具有吸收的另一种波长。 980nm。更安全/改进的方法/系统提供增强的碎石治疗，治疗时间更短，以破坏更广泛的石块，减少组织损伤风险。

46. 发明申请

US20110275979A1 METHOD/DEVICE FOR TRANSDERMAL VASCULAR TREATMENT 有权
标题翻译：用于超声波血管治疗的方法/装置
公开(公告)号：US20110275979A1
公开(公告)日：2011-11-10
申请号：US12992533
申请日：2009-05-15
申请人： Jorge O. López D'Ambola , Jorge E. Soracco , Wolfgang Neuberger
发明人： Jorge O. López D'Ambola , Jorge E. Soracco , Wolfgang Neuberger
IPC分类号： A61M37/00 , A61N5/067
CPC分类号： A61B18/203 , A61B18/20 , A61B18/22 , A61B2017/00765 , A61B2018/00452 , A61B2018/00458 , A61B2018/202 , A61B2018/2065 , A61N5/062 , A61N2005/007 , A61N2005/0651 , A61N2005/0659
摘要： Devices and transdermal methods are provided for safe and effective therapeutic treatment of the venous system, such as varicose veins. Present invention provides non-invasive and minimally invasive transdermal methods for treating varicose and spider veins, comprising the use of a radiation source in combination with a chemical fluid/composition to safely and more effectively close or shrink vein walls, providing a transdermal therapeutic method for varicose veins until now only treated with surgery or endovascular laser treatments. In a preferred embodiment a device comprises a radiation source, preferably of wavelength between about 980 and 1940 nm, being effective in causing shrinkage of the vein treated. In other preferred embodiments methods comprise the transdermal delivery of a chemical composition through a patch or gel or the injection of a chemical fluid, preferably a hypertonic solution, to the vein under treatment; and simultaneously or after a dwell time, irradiating with a radiation source transdermally. The treatment performed with the present invention results in blood vessel wall damaged, eventually closing the vein, in lesser time with practically no pain or discomfort to the patient during and after the therapy.
摘要翻译：提供装置和透皮方法用于对静脉系统进行安全和有效的治疗，例如静脉曲张。本发明提供用于治疗静脉曲张和蜘蛛静脉的非侵入性和微创透皮方法，其包括使用辐射源与化学液体/组合物组合以安全且更有效地闭合或收缩静脉壁，提供透皮治疗方法静脉曲张直到目前为止只用手术或血管内激光治疗。在优选实施例中，装置包括辐射源，优选波长在约980和1940nm之间，有效地引起所治疗静脉的收缩。在其它优选实施方案中，方法包括通过贴剂或凝胶透皮递送化学组合物或将化学流体（优选高渗溶液）注射到处理的静脉中; 并且在停留时间之后或之后，经皮肤照射辐射源。用本发明进行的治疗导致血管壁受损，最终在较短的时间内关闭静脉，实际上在治疗期间和之后患者没有疼痛或不适。

47. 发明申请

US20110196356A1 ABLATIVE/COAGULATIVE UROLOGICAL TREATMENT DEVICE AND METHOD 审中-公开
标题翻译：摘要/凝血治疗装置及方法
公开(公告)号：US20110196356A1
公开(公告)日：2011-08-11
申请号：US12882758
申请日：2010-09-15
申请人： Wolfgang Neuberger
发明人： Wolfgang Neuberger
IPC分类号： A61B18/22
CPC分类号： A61B18/22 , A61B18/18 , A61B18/1815 , A61B2017/00274 , A61B2018/00547 , A61B2018/00577 , A61B2018/00589 , A61B2018/1861 , A61N5/02
摘要： A device/system and a method of treating enlarged prostate and other urologic abnormalities are presented. A combined treatment is performed with several interstitial coagulating probes and an ablating fiber. Tissue vaporization is minimized by the denaturalizing effect of interstitial coagulative fibers. In a single device, multiple delivery systems achieve optimal tissue ablation/coagulation; a non-laser source like microwave energy coagulates tissue and a laser source ablates tissue. Another device comprises two or more laser sources with adjustable wavelengths controllable by physician as to ablative, coagulative, and tissue penetration needs. Continuous, semi-continuous, pulsed wave, or combinations are useful. In another embodiment, optical fiber has a central core for transmitting laser radiation, and a cladding layer about the core that may further transmit other laser radiation of a different or a same wavelength as the core. Fibers may have a side-firing distal end, a radial firing end, or an off-axis firing end. Feedback controls can be used. In general coagulative irradiation can use a radiofrequency or other radiant thermal source.
摘要翻译：提出了一种治疗放大的前列腺和其他泌尿系统异常的装置/系统和方法。用几个间质凝结探针和消融纤维进行联合治疗。组织蒸发通过间质凝固纤维的变性作用最小化。在单个装置中，多个递送系统实现最佳的组织消融/凝血; 诸如微波能量的非激光源凝结组织，激光源消融组织。另一个装置包括两个或更多个具有可调波长的激光源，可由医师控制，以消融，凝固和组织穿透需要。连续，半连续，脉冲波或组合是有用的。在另一个实施例中，光纤具有用于传输激光辐射的中心芯和围绕芯的包覆层，其可以进一步透射与芯不同或相同波长的其他激光辐射。纤维可以具有侧发射远端，径向射击端或离轴射击端。可以使用反馈控制。一般来说，凝结照射可以使用射频或其他辐射热源。

48. 发明申请

US20110172652A1 METHOD AND DEVICE FOR UNDERSKIN RADIATION TREATMENT OF ADIPOSE TISSUE 有权
公开(公告)号：US20110172652A1
公开(公告)日：2011-07-14
申请号：US12987416
申请日：2011-01-10
申请人： Wolfgang Neuberger
发明人： Wolfgang Neuberger
IPC分类号： A61B18/22
CPC分类号： A61B18/22 , A61B2018/0019 , A61B2018/00994 , A61B2018/2005 , A61B2018/2272
摘要： A method and device for underskin treatment and removal of adipose tissue by means of a radiation energy source is disclosed. The method disclosed of radiation-assisted tissue improvement consists of inserting a device or part of a device below the skin into areas to be treated, emitting radiation and moving the device within tissue area to reach all parts. The method is characterized by emitting radiation at intensity levels low enough to practically avoid or minimize carbonization in the main tissue components such as fat and connective tissue but at sufficient intensity to enable coagulation of smaller blood vessels thus preventing from bleeding at the spectrum emitted. Thus, in preferred embodiments, power density is kept at up to about 2 W/mm. This allows for use of small diameter fibers such as 400 μm or less. The device for carrying out underskin radiation treatment consists of a handpiece that allows easy manipulation by physicians, with a part that can be inserted below the skin and a part that can be held and manipulated outside the body. The part inserted below the skin can be vibrated or oscillated by means of suitable transducers to aid in distributing the radiation. Simultaneously or immediately afterwards, liquefied tissue is aspirated. If convenient, fluid irrigation of the area to be treated can be done. In a preferred embodiment, handpiece consists in a hollow cannula incorporating at least one channel for suction and/or irrigation and a light guiding means in its body/wall section for the purpose of the treatment and liquefaction of adipose tissue. Due to handpiece's special configuration, a wide variety of fiber tip configurations can be used, i.e. side emitting, conical, radial emitting, drop shaped, reflective caps, but not limited thereto. Each fiber tip configuration allows for optimally performing different specific treatments. The device further comprises at least one radiation source, included in device part affixed to the handpiece either in a permanent or detachable manner.

49. 发明申请

US20110160713A1 TWISTER FIBER OPTIC SYSTEMS AND THEIR USE IN MEDICAL APPLICATIONS 有权
公开(公告)号：US20110160713A1
公开(公告)日：2011-06-30
申请号：US12714155
申请日：2010-02-26
申请人： Wolfgang Neuberger
发明人： Wolfgang Neuberger
IPC分类号： A61B18/22
CPC分类号： A61B18/22 , A61B2018/0019 , A61B2018/1861 , A61B2018/2211 , A61B2018/2272 , A61B2018/2288
摘要： An improved device and method for safe, accurate and efficient surgical procedures are disclosed. The disclosed device is an optical fiber set with an asymmetric distal end configuration, comprising a bent tip fiber with a fused sleeve as an integral part of it, placed at the fiber's distal (output) end and with a rotatable connector at the proximal (input) side. Fiber tip and tissue-contacting surface located at the distal end of the tip may be constructed with different shape configurations, such as convex tip to improve focusing characteristics, concave tip to achieve diverging irradiation or an expanded beam tip to achieve an effect similar to that obtained by electrosurgical tools. A grip guarantees and enhances the ability to twist and rotate it easily. In another preferred embodiment, twisting maneuvers are enhanced through a special configuration. Both special features (bent tip and rotatable connector), allow for improved and enhanced treatment of diverse pathologies, making possible to efficiently and easily reach and treat specific tissues. Optical fiber's steerability, twistability and rotation lead to a more precise and improved effect on tissues. Due to this, easier, faster and more precise and efficient treatments can be performed by its means. For instance, it may be inserted into a cystoscope to perforin high power ablation of prostatic tissue for BPH treatments, or steered into one of the prostatic lobes, which can be excavated from the inside in order to relieve pressure on the urethra while maintaining the urethra's integrity. Other uses might be the removal of tumorous, hyperplasic or other unwanted tissue in the body. Optical fiber set disclosed can be used with laser sources of various wavelengths, including dual laser sources, but also higher power LED devices or very bright light sources can be used to generate the radiation to be transmitted as well. Due to this novel design, described fiber is easy to put in place, also easy to maintain in contact with tissue and highly durable. The feel to the doctor is greatly improved too. This results in more effective power transfer into tissue and therefore procedures are more reliable and procedure times are cut by up to 30%.

50. 发明申请

US20110160642A1 PEGYLATED LIPOSOMAL FORMULATIONS FOR PHOTODYNAMIC TREATMENT OF INFLAMMATORY DISEASES 审中-公开
标题翻译：用于荧光动力治疗炎性疾病的聚乙二醇脂质体制剂
公开(公告)号：US20110160642A1
公开(公告)日：2011-06-30
申请号：US12742336
申请日：2008-11-14
申请人： Wolfgang Neuberger , Volker Albrecht
发明人： Wolfgang Neuberger , Volker Albrecht
IPC分类号： A61M37/00 , A61K9/127 , A61K31/409 , A61P29/00 , A61P19/02
CPC分类号： A61K9/1271 , A61K41/0071 , A61K47/6911
摘要： A PDT treatment system designed to treat all types of human inflammatory disorders. A suitable drug delivery system is developed to target proliferating cells, at inflamed sites, populated with macrophages and other inflammatory mediators. The hydrophobic photosensitizer is loaded into the liposomal bilayer formed of synthetic phospholipids; at least one of the synthetic phospholipids is conjugated to polyethylene glycol (PEG) molecules, to prevent accumulation in the liver and spleen. Further, (PEG) formulated photosensitizer increases the circulatory half-life of the drug, enhances solubility, and modifies pharmacokinetic and pharmacodynamic properties. The formulation, thus, leads to a higher amount of delivered drug to the diseased target synovial tissue, increasing clinical effectiveness. In one embodiment, pegylated liposomes loaded with mTHPC are administered to diseased synovial joints, followed by light irradiation. Activated photosensitizer induces cytotoxic effect in the diseased synovial cells, thus preventing further inflammation and joint erosion and minimizing joint damage.
摘要翻译：设计用于治疗所有类型的人类炎症性疾病的PDT治疗系统。开发合适的药物递送系统以靶向增殖细胞，在发炎部位，富含巨噬细胞和其他炎症介质。将疏水性光敏剂加载到由合成磷脂形成的脂质体双层中; 至少一种合成磷脂与聚乙二醇（PEG）分子缀合，以防止在肝脏和脾脏中积累。此外，（PEG）配制的光敏剂可增加药物的循环半衰期，增强溶解性，并改变药代动力学和药效学性质。因此，该制剂导致更高量的递送药物到患病的目标滑液组织，增加临床有效性。在一个实施方案中，将装载有mTHPC的聚乙二醇化脂质体施用于患病的滑膜关节，随后进行光照射。活化的光敏剂在患病的滑膜细胞中诱导细胞毒性作用，从而防止进一步的炎症和关节侵蚀并最小化关节损伤。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式